Year-End Sale is Live! Find Exclusive Prices on the Best Selling Pharma & MedTech Reports.

Check Now !

Allergic Rhinitis Pipeline Insight

DelveInsight’s, “Allergic Rhinitis - Pipeline Insight, 2021,” report provides comprehensive insights about 35+ companies and 35+ pipeline drugs in Allergic Rhinitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Allergic Rhinitis Understanding

Allergic Rhinitis: Overview

Allergic Rhinitis, or hay fever, is an allergic response to specific allergens. Common symptoms of Allergic Rhinitis include sneezing, runny nose, coughing, sore or scratchy throat, itchy eyes, watery eyes, dark circles under the eyes, frequent headaches, eczema-type symptoms, hives, and excessive fatigue. Allergic Rhinitis is usually a long-standing condition that often goes undetected in the primary-care setting. A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of Allergic Rhinitis. Treatment of Allergic Rhinitis is symptomatic and depends on the type of allergen. Management incudes medication like intranasal corticosteroids, antihistamines, decongestants, immunotherapy, eye drops and nasal sprays. Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment.


"Allergic Rhinitis - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Allergic Rhinitis pipeline landscape is provided which includes the disease overview and Allergic Rhinitis treatment guidelines. The assessment part of the report embraces, in depth Allergic Rhinitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Rhinitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Allergic Rhinitis R&D. The therapies under development are focused on novel approaches to treat/improve Allergic Rhinitis.

Allergic Rhinitis Emerging Drugs Chapters

This segment of the Allergic Rhinitis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Allergic Rhinitis Emerging Drugs


REGN5713-5714-5715: Regeneron Pharmaceuticals

REGN5713-5714-5715 is a cocktail of three Bet v1 monoclonal antibodies. Regeneron Pharmaceuticals is investigating REGN5713-5714-5715 as intravenous injections in Phase III clinical studies for the treatment of Allergic Rhinitis and conjunctivitis.


Injectable MPL allergy vaccine: Allergy Therapeutics

Injectable MPL allergy vaccine is a subcutaneously administered vaccine containing glutaraldehyde-modified allergens and the adjuvants 3-deacylated monophosphoryl lipid A (MPL) and L-tyrosine. The drug is in Phase II/III clinical developmental studies for the treatment of Seasonal Allergic Rhinitis.

Further product details are provided in the report……..

Allergic Rhinitis: Therapeutic Assessment

This segment of the report provides insights about the different Allergic Rhinitis drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Allergic Rhinitis

There are approx. 35+ key companies which are developing the therapies for Allergic Rhinitis. The companies which have their Allergic Rhinitis drug candidates in the most advanced stage, i.e. Phase III include, Regeneron Pharmaceuticals.

Phases

DelveInsight’s report covers around 35+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Allergic Rhinitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Allergic Rhinitis therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Allergic Rhinitis drugs.

Allergic Rhinitis Report Insights

  • Allergic Rhinitis Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Allergic Rhinitis Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Allergic Rhinitis drugs?
  • How many Allergic Rhinitis drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Allergic Rhinitis?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Allergic Rhinitis therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Allergic Rhinitis and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Allergic Rhinitis: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Allergic Rhinitis – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

  • Allergic Rhinitis companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Allergic Rhinitis Collaboration Deals

  • Company-Company Collaborations (Licensing / Partnering) Analysis
  • Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

  • Comparative Analysis

REGN5713-5714-5715: Regeneron Pharmaceuticals

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II/III)

  • Comparative Analysis

Injectable MPL allergy vaccine: Allergy Therapeutics

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

B 244: AOBiome

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical/Discovery Stage Products

  • Comparative Analysis

MM09-MG01: Immunotek

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Allergic Rhinitis Key Companies

Allergic Rhinitis Key Products

Allergic Rhinitis- Unmet Needs

Allergic Rhinitis- Market Drivers and Barriers

Allergic Rhinitis- Future Perspectives and Conclusion

Allergic Rhinitis Analyst Views

Allergic Rhinitis Key Companies

Appendix

List of Table

Table 1: Total Products for Allergic Rhinitis

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Allergic Rhinitis

Figure 2: Late Stage Products                               

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products    

• Abdi Ibrahim Pharmaceuticals

• Allergy Therapeutics

• Regeneron Pharmaceuticals

• Laboratorios LETI

• ALK-Abello

• Advagene Biopharma

• CSPC ZhongQi Pharmaceutical Technology

• Array BioPharma

• Immunotek

Forward to Friend

Need A Quote